U.S. stocks were indicated lower on Wednesday morning ahead of key inflation data and after the presidential debate. While September is historically the weakest month of the year for stocks, both long-term investors and short-term traders are still on the hunt for new investing ideas ahead of the coming interest rate cuts expected next week. Tactical Bulls is always looking to find some of those new ideas inside the daily flow of Wall Street research reports.

Analyst reports can be one of the sources for finding new ideas that might have otherwise been overlooked or missed. Long-term investors get a picture of new buy, sell and hold ratings. Short-traders get a glimpse of how the moves are looking on a live basis.

Tactical Bulls would remind its readers and all investors that no single analyst report should ever be used as the sole reason to buy or sell a stock. That decision to buy, sell or hold ultimately needs to be made by each investor along with their financial advisor.

These are some of the top analyst upgrades and downgrades seen on Wednesday, September 11, 2024.

AES Corporation (NYSE: AES) was started as a Buy with a $20 price target (versus $16.44 prior close) at Jefferies.

Antero Resources Corporation (NYSE: AR) was raised to Outperform from Peer Perform with a $37 price target (versus $25.25 prior close) at Wolfe Research.

Ally Financial Inc. (NYSE: ALLY) shares closed down 17.6% at $32.67 on Tuesday after the financial lender noted that consumers are struggling and delinquencies are rising. BofA Securities maintained its Buy rating but cut its price objective to $37 from $46 in its call. Morgan Stanley maintained its Overweight rating but cut its price target to $45 from $49.

AppLovin Corporation (NASDAQ: APP) was reiterated as Buy and its price objective was raised to $120 from $100 (versus $86.23 prior close) at BofA Securities.

Beam Therapeutics Inc. (NASDAQ: BEAM) was reiterated as Buy and its price target was raised to $69 from $66 (versus $23.65 prior close) at Stifel.

Civitas Resources, Inc. (NYSE: CIVI) was maintained as Overweight but its price target was trimmed down to $84 from $85 (versus $53.09 prior close at Piper Sandler.

Elastic N.V. (NYSE: ESTC) was started with a Buy rating and was assigned a $100 price target (versus $72.09 prior close) at Guggenheim.

GameStop Corp. (NYSE: GME) was last seen down 10% at $21.00 after its earnings report. Wedbush Securities maintained its Underperform rating and $11 price target after noting that it still faces challenges in growth and the challenge of games switching to digital.

Haemonetics Corporation (NYSE: HAE) was started as Neutral at BofA Securities.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) was reiterated as Buy but its price target was cut to $64 from $80 (versus $20.12 prior close) at Stifel.

Morgan Stanley (NYSE: MS) was downgraded to Neutral from Buy and the price target was cut to $105 from $122 (versus $96.62 prior close) at Goldman Sachs.

Novartis AG (NYSE: NVS) was downgraded to Neutral from Buy and the price objective was cut to $130 from $135 (versus $116.99 prior close) at BofA Securities.

Supernus Pharmaceuticals, Inc. (NASDAQ: SNUS) was downgraded to Neutral from Overweight and its price target was cut to $36 from $41 (versus $33.49 prior close) at Piper Sandler.

If you missed Tuesday’s top analyst calls they were in shares of Apple, Costco, Dell, GE, Meta, Oracle, Tesla and many more stocks.